Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2022 | The value of blinatumomab in ALL and future therapeutic considerations

Marlise Luskin • 28 Sep 2022

SOHO 2022

Acute Lymphoblastic Leukemia Leukemia Antibodies Asparaginase Blinatumomab Vincristine

Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses treatment approaches for patients with acute lymphoblastic leukemia (ALL), highlighting the value of blinatumomab in the ALL treatment armamentarium. Dr Luskin also shares her thoughts on important questions surrounding the future use and sequencing of this agent. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Venetoclax & dose-reduced chemotherapy for the treatment of older adults with B-ALL and T-ALL

Marlise Luskin • 10 Dec 2023

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trial

Marlise Luskin • 10 Dec 2023

Asciminib plus dasatinib for the treatment of Ph+ B-ALL: insights from a Phase I trial

Marlise Luskin • 10 Dec 2023

Long-term overall survival of AYA patients with ALL who complete therapy on DFCI Consortium trials

Marlise Luskin • 11 Dec 2022

Related Videos

The development of iNKT-CAR T-cells for hematological malignancies

Kanagaraju Ponnusamy • 29 Apr 2024

BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948

Dima El-Sharkawi • 28 Apr 2024

Increasing awareness of germline predispositions to hematological malignancies in pediatric patients

Anupama Rao • 29 Apr 2024

The development of a UK AML registry

Priyanka Mehta • 22 Apr 2024